Cyclohexylamine inhibits the adhesion of lymphocytic cells to human syncytiotrophoblast. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Cyclohexylamine inhibits the adhesion of lymphocytic cells to human syncytiotrophoblast.

Biochim Biophys Acta. 1995 May 12;1266(3):229-34. Unique Identifier : AIDSLINE MED/95284136
Douglas GC; Hu J; Thirkill TL; Hovanes K; Fuller M; King BF; Department of Cell Biology and Human Anatomy, School of Medicine,; University of California, Davis 95616-8643, USA.


Abstract: We have previously shown that lymphocytic cells adhere to cultured syncytiotrophoblast and that this may be important in the lymphocyte-mediated infection of trophoblast with the human immunodeficiency virus (HIV). During the course of studies aimed at investigating the role of cell surface carbohydrates in adhesion, it was discovered that a contaminant of commercial fucose-1-phosphate, dicyclohexylamine, inhibited MOLT-trophoblast adhesion. Dicyclohexylamine and the related compounds, cyclohexylamine and hexylamine, inhibited adhesion in a dose-responsive manner with half-maximal inhibition seen at about 4 mM. While the pressor effects of cyclohexylamine, the principal metabolite of cyclamate, are well known, this is the first report of an effect of this and related compounds on cell adhesion activity. The inhibitory effect was reversible and, at concentrations less than 25 mM, did not result in loss of cell viability. Several possible mechanisms of action of cyclohexylamine were examined in an attempt to explain the effect on adhesion. No evidence was found to suggest that the effects of cyclohexylamine were due to inhibition of polyamine synthesis, increase in intracellular Ca2+ concentration or to a lysosomotropic effect. The concentrations of cyclohexylamine used are within the range of plasma concentrations attainable in humans, raising the possibility that the in vitro effects described here may also occur in vivo. The results also suggest that caution should be used in the interpretation of results obtained from experiments where cell adhesion is blocked using exogenous monosaccharides that are in the form of dicyclohexylammonium salts. Appropriate controls must be included or, if possible, sodium, potassium or barium salts should be chosen.
Keywords: Cell Adhesion/*DRUG EFFECTS Clone Cells Cyclohexylamines/*CHEMISTRY/*PHARMACOLOGY Dose-Response Relationship, Drug Fructosephosphates/PHARMACOLOGY Fucose/*ANALOGS & DERIVATIVES/CHEMISTRY Hexosephosphates/*CHEMISTRY Human Lymphocytes/DRUG EFFECTS Support, U.S. Gov't, P.H.S. Trophoblast/CYTOLOGY JOURNAL ARTICLEKWDcelladhesion/KWDdrugeffectsclonecellscyclohexylamines/KWDchemistry/KWDpharmacologydose-responserelationship,drugfructosephosphates/pharmacologyfucose/KWDanalogs&derivatives/chemistryhexosephosphates/KWDchemistryhumanlymphocytes/drugeffectssupport,uKWDsKWDgov't,pKWDhKWDsKWDtrophoblast/cytologyjournalarticle
950930
M9590823

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .